Genotype®MTBDRplus and Xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis : cost analysis in a tertiary referral hospital.
Nenhuma Miniatura disponível
Data
2020
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Introduction: The present study sought to assess the mean and activity based cost (ABC) of the laboratory diagnosis for tuberculosis
through the application of conventional and molecular techniques—Xpert®MTB/RIF and Genotype®MTBDRplus—in a tertiary referral
hospital in Brazil. Methods: The mean cost and ABC formed the basis for the cost analysis of the TB laboratory diagnosis. Results:
The mean cost and ABC were US$ 4.00 and US$ 3.24, respectively, for a bacilloscopy; US$ 6.73 and US$ 5.27 for a Lowenstein-Jensen
(LJ) culture; US$ 105.42 and US$ 76.56 for a drug sensitivity test (DST)–proportions method (PM) in LJ; US$ 148.45 and US$ 136.80
for a DST–BACTECTM MGITTM 960 system; US$ 11.53 and US$ 9.89 for an Xpert®MTB/RIF; and US$ 84.21 and US$ 48.38 for a
Genotype®MTBDRplus. Conclusions: The mean cost and ABC proved to be good decision-making parameters in the diagnosis of TB
and MDR-TB. The effective implementation of algorithms will depend on the conditions at each location.
Descrição
Palavras-chave
Mycobacteria, Mean cost, Activity based cost
Citação
SOARES, V. M. et al. Genotype®MTBDRplus and Xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis: cost analysis in a tertiary referral hospital. Revista da Sociedade Brasileira de Medicina Tropical, v. 53, 2020. Disponível em: <https://www.scielo.br/j/rsbmt/a/6sQTBmPbkDXcLYvBNhjdJmG/?lang=en>. Acesso em: 11 out. 2022.